Skip to main content
. 2018 Dec;10(12):6677–6694. doi: 10.21037/jtd.2018.11.87

Figure S4.

Figure S4

Probability of treatment rankings for the analysis of progression-free survival, hazard ratio analysis, excluding carbo + S-1. Carbo, carboplatin; cis, cisplatin; doc, docetaxel; erlot, erlotinib; gem, gemcitabine; nab-tax, nab-paclitaxel; neci, necitumumab; tax, paclitaxel; vin, vinorelbine.